COMMUNITY ADVOCATES TO PROTEST HEPATITIS C PROFITEERING BY GILEAD SCIENCES, INC. AT J.P. MORGAN’S 34th ANNUAL HEALTHCARE CONFERENCE

PRESS RELEASE

COMMUNITY ADVOCATES TO PROTEST HEPATITIS C PROFITEERING BY GILEAD SCIENCES, INC. AT J.P. MORGAN’S 34th ANNUAL HEALTHCARE CONFERENCE

DATE: MONDAY 11 JANUARY 2016 at 12 NOON

PLACE: WESTIN ST. FRANCIS Hotel, 335 POWELL ST., SAN FRANCISCO

Background:

Gilead Sciences, Inc. is a leading developer of hepatitis C medications, a condition that affects about 5 million persons in the U.S. and 170 million persons worldwide.  An 18-month investigation by the Senate Finance Committee, under the leadership of Ranking Member Ron Wyden (D-Ore.) and Senator Chuck Grassley (R-Iowa) revealed that Gilead’s “pricing and marketing strategy [was] designed to maximize revenue with little concern for access or affordability,” concluding that “Gilead pursued a calculated scheme for pricing and marketing its hepatitis C drug based on one primary goal, maximizing revenue, regardless of the human consequences.”

The costs to America’s health system have been staggering, and recent restrictions in Gilead’s patient assistance program have left thousands of persons without access to medications and at risk for cirrhosis, liver cancer, and death.

A coalition of hepatitis C community will protest Gilead’s profiteering at the 34th Annual J.P. Morgan Healthcare Conference, a gathering of corporate healthcare leaders, financial sponsors and institutional investors. “Gilead is ripping off the healthcare system and promoting patient suffering,” says Dr. Diana Sylvestre, Executive Director of the O.A.S.I.S. Clinic in Oakland, CA.  “It’s time to value public health over corporate wealth and we intend to make this clear to corporate leaders and investors.”

About Hepatitis C

Hepatitis C is a bloodborne virus that affects about 5 million people in the U.S. and 170 million worldwide.  Untreated, it can lead to cirrhosis, liver cancer, and death.  New treatments can lead to cure in over 90% of patients.

About the O.A.S.I.S. Clinic

O.A.S.I.S. is a 501(c)3 not-for-profit clinic located in Oakland, CA, recognized for treating marginalized persons with hepatitis C.

CONTACT: Diana Sylvestre, MD at 415-271-1642 or diana.sylvestre@ucsf.edu

Labels: , ,